Hypertension
Conditions
Interventions
Administration of losartan (standard dose)/hydrochlorothiazide combination
Administration of losartan alone (high-dose)
Sponsors
National Defense Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Hypertensive patients whose blood pressures did not reach the levels recommended by Hypertension Guidelines 2009 of Japanese Association of Hypertension, even when administered standard doses of angiotensin receptor blokers. 2) Outpatients 3) Subjects who gave written informed consent
Exclusion criteria
Exclusion criteria: 1)Allergy against losartan/hydrochlorothiazide 2)Poor-controlled hypertension (DBP>110 mmHg) 3)Poor-controlled diabetes (HbA1c>8.0 %) 4)Secondary hypertension 5)History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 6)Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits. 7)End stage renal disease 8)Symptomatic (NYHA III or IV) congestive heart failure 9)Malignancies or other diseases with poor prognosis 10)Pregnant 11)Subjects whose doctor in charge do not agree to join the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure (Office/Home monitoring) Flow-mediated vasodilation in forearm Heparin-releasable EC-SOD levels Twelve and Twenty four weeks after administration | — |
Secondary
| Measure | Time frame |
|---|---|
| Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria) Twelve weeks and Twenty four after administration | — |
Countries
Japan
Contacts
Public ContactMakoto Ayaori
National Defense Medical College Department of Internal Medicine I
Outcome results
None listed